Explore

Trendline Trendline
Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026

Marea Therapeutics to Present Phase 1 Study Results of MAR002 for Acromegaly at ENDO 2026
Trendline Trendline
InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies

InduPro Therapeutics Names Amanda J. Redig as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer to Advance Cancer Therapies
Trendline Trendline
Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting

Citius Oncology Presents Promising Phase 1 Data on LYMPHIR at ASCO Meeting
Trendline Trendline
Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors

Adcendo and MSD Collaborate on Phase Ib Study for Advanced Solid Tumors
Trendline Trendline
Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity

Kura Oncology's New Cancer Drug Shows Promise, Potential $2 Billion Market Opportunity
Trendline Trendline
Alkermes to Present New Data on Psychiatric Treatments at ASCP Annual Meeting

Alkermes to Present New Data on Psychiatric Treatments at ASCP Annual Meeting

Alkermes to Present New Data on Psychiatric Treatments at ASCP Annual Meeting
Trendline Trendline
Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies

Delphia Therapeutics Appoints David P. Kerstein as Chief Medical Officer to Advance Cancer Therapies
Rapid Read Rapid Read
FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

FDA Approves Brenus Pharma's IND Application for STC-1010 in Metastatic Colorectal Cancer

Brenus Pharma, a biotechnology company specializing in immuno-oncology, has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for STC-1010. This drug is designed to treat microsatellite stable (MSS) metastatic colorectal cancer (mCRC), a condition affecting approximately 95% of mCRC patients who typically show minimal response to standard immunotherapies. The FDA's approval allows Brenus Pharma to proceed with clinical evaluations in the U.S. under the BreAK-CRC001 study. This development follows European regulatory approvals and initial positive results from early Phase Ia trials. The company plans to present further data at the ESMO annual congress in 2026.
Trendline Trendline
D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment

D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment

D Pharmatech Reports Positive Results for Zabopegdutide in MASH Treatment
Trendline Trendline
Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients

Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients

Crystalys Therapeutics Initiates Phase 2 Trial for Dotinurad in Gout Patients
Trendline Trendline
Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment

Agios Pharmaceuticals Secures EU Approval for PYRUKYND in Thalassaemia Treatment